Skip to main content

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Publication ,  Journal Article
Laskowitz, DT; Kolls, BJ
Published in: Neurology
June 15, 2010

Duke Scholars

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

June 15, 2010

Volume

74

Issue

24

Start / End Page

2026

Location

United States

Related Subject Headings

  • Neurology & Neurosurgery
  • Humans
  • Dose-Response Relationship, Drug
  • Clinical Trials, Phase II as Topic
  • Apolipoprotein E4
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Alzheimer Disease
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Laskowitz, D. T., & Kolls, B. J. (2010). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 74(24), 2026. https://doi.org/10.1212/WNL.0b013e3181e03844
Laskowitz, Daniel T., and Brad J. Kolls. “A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.Neurology 74, no. 24 (June 15, 2010): 2026. https://doi.org/10.1212/WNL.0b013e3181e03844.
Laskowitz, Daniel T., and Brad J. Kolls. “A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.Neurology, vol. 74, no. 24, June 2010, p. 2026. Pubmed, doi:10.1212/WNL.0b013e3181e03844.

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

June 15, 2010

Volume

74

Issue

24

Start / End Page

2026

Location

United States

Related Subject Headings

  • Neurology & Neurosurgery
  • Humans
  • Dose-Response Relationship, Drug
  • Clinical Trials, Phase II as Topic
  • Apolipoprotein E4
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal
  • Alzheimer Disease
  • 3209 Neurosciences
  • 3202 Clinical sciences